Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
about
Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugsReceptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell LinesDeconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells.The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review.Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition.Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cellsChemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinibPhase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast CancerPreclinical validation of a novel compound targeting p70S6 kinase in breast cancer.First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.Combine and conquer: challenges for targeted therapy combinations in early phase trials.PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells.ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2+ Breast Cancer Cells.Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.Efficacy of buparlisib in treating breast cancer.Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer.LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer.Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy
P2860
Q27303674-C6F1124F-9751-41A6-AFC3-2F64A2B838FCQ27853122-B81B5A58-DB7B-4218-AE7D-C2EEF2A9E949Q28546221-8991475C-AB70-41C2-A04B-8243235956A3Q30841629-7155D49A-8E02-4103-AA4B-311EB195A05CQ34227776-9899CA65-B419-4760-8BBC-83698560BBE2Q34373936-5EF42057-CD66-4EE2-87EE-1CDF0B542DECQ35077393-F330C6A0-9CC4-4CAD-AB10-BDFF76946AADQ35839063-9ED11E26-8A08-4647-9402-52B94FEA70D6Q35843230-FE170063-184E-48F3-89D2-FFD0A26BF406Q36258125-E81A1B57-E703-46DE-B8AC-74E18F52F24DQ36485168-4FE295EF-2625-4CEA-910B-84327A35BF17Q36562299-602BFDBE-D5D9-42FB-9AAD-2819AB416B43Q36963374-487586FD-D2E8-4919-BE65-6469B0B4DAA0Q37062488-5386BCD2-119C-4C34-A2A5-41036BE867DFQ37281257-FAF2FF74-A494-41C3-8A36-B926D4BC7403Q37578324-94D63CE9-1F15-4208-80D0-06320AC6C5F1Q38554422-15DC607E-A3CF-49E7-83EA-E0C06D2759FDQ38656763-E1E544AD-B3C2-4654-890D-B09485760E38Q38734451-7BB5A3F6-FF16-4787-AB45-8C294BE087A8Q38752291-C52833A5-191E-4E6A-8241-AC004CC58DF2Q38824661-40E05B96-20A2-4395-B268-BC771972B9A1Q38911605-D181E2FF-3F37-4896-8858-657BB4FFA9F8Q41846641-E1403F0C-1A83-4A93-8345-78DFA2928966Q47350657-6E016D41-B890-4BCD-A0AA-F7195A39B089Q47938353-3832988E-7E29-4110-A33E-4191F6B49113Q48095126-C06A365F-9D17-4CC1-A61C-76BD69AC832CQ49711965-55249283-7F5A-42DD-AAF8-9BD6CE044F17Q53681633-E8A70FE5-52F8-4753-BFD9-ED2C40E190DCQ53686361-80A27B9D-146C-4412-B6E0-59A189DB9B40Q54112795-6B09B409-4E54-4121-AC60-64C8D3260181Q54979012-8CCB449D-84FC-41BF-9927-BF4081B4DB8FQ55479657-2DB17C3D-02A2-4E53-8EA0-4CA902FC1A01Q57072192-0AC3BFBA-C847-4EC1-BE4E-A0044F91A97F
P2860
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Targeting PI3K/mTOR overcomes ...... of feedback activation of AKT.
@en
type
label
Targeting PI3K/mTOR overcomes ...... of feedback activation of AKT.
@en
prefLabel
Targeting PI3K/mTOR overcomes ...... of feedback activation of AKT.
@en
P2093
P1476
Targeting PI3K/mTOR overcomes ...... of feedback activation of AKT.
@en
P2093
Christian Schnell
Dennis J Slamon
Dylan Conklin
Emmanuelle di Tomaso
Erika von Euw
Karen McDonald
Neil A O'Brien
Richard S Finn
Ronald Linnartz
P304
P356
10.1158/1078-0432.CCR-13-2769
P407
P577
2014-05-30T00:00:00Z